Actively Recruiting
Clinical Aspects, Management and Surveillance of Febrile Illnesses in the Democratic Republic of Congo
Led by Institute of Tropical Medicine, Belgium · Updated on 2026-01-15
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating febrile illnesses in the Democratic Republic of Congo (DRC), focusing on their causes, clinical features, and outcomes. This study builds on the previous FIKI b2 study, which examined fever-related diseases and the use of inflammatory markers like C-reactive protein (CRP) to manage antibiotic use better. It aims to assess the impact of CRP testing, the WHO's AWARE antibiotic guidance, and electronic decision tools on antibiotic prescribing in primary care settings, while also strengthening research capacity and biobanking in the region. The study is observational and involves multiple centers, starting with pediatric emergency and outpatient departments. It recruits adults and children presenting with fever, collecting clinical and laboratory data at the initial visit and during a three-week follow-up. Laboratory samples are stored for further research, including blood cultures and testing for viral infections like arboviruses. The study uses systematic clinical assessment, biomarker measurement, and surveillance tools to deepen understanding and improve management of febrile illnesses. Participants will undergo blood tests for CRP, white blood cell counts, malaria detection, and other routine labs. Data on symptoms, clinical presentation, and treatment adherence are collected at enrollment and through follow-up visits on days 7, 14, and 21. Researchers will analyze antibiotic use, illness severity, hospital admissions, and outcomes, aiming to improve fever management and reduce inappropriate antibiotic use across study sites. The total participation lasts approximately three weeks with continued monitoring during this period.
CONDITIONS
Brief Title
Clinical Aspects, Management and Surveillance of Febrile Illnesses in DRC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ongoing fever at presentation or documented fever within 24 hours before presentation, defined as axillary or tympanic temperature > 37.5�b0C, or oral or rectal temperature > 38�b0C
- Ability to be contacted for follow-up on days 7, 14, and 21 by the patient or a designated relative
- Signed informed consent by the patient or legal representative, with assent from children aged 12 and over when possible
You will not qualify if you...
- Child younger than two months old
- Hospitalization for more than 48 hours within the last 14 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 weeks
Participants are observed with data collection on clinical and laboratory characteristics at the time of consultation and during a three-week follow-up period.
Follow-up contacts on days 7, 14, and 21
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Universitaire Renaissance
Kinshasa, Democratic Republic of the Congo
Actively Recruiting
Research Team
E
Emmanuel Bottieau, PhD
S
Steven Declercq, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here